Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%
BP

BridgeBio Pharma, Inc. (BBIO)

NASDAQ • Healthcare

$78.01
+$1.21 (+1.6%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$76.45
Day Range$75.99 - $78.25
Avg. Volume (3M)3M
Market Cap$15.1B
52 Week Range
$62.5$93.42

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$353.1M100%
Gross Profitminus cost of goods$332.7M94%

In plain terms: out of every $100 in revenue, BridgeBio Pharma, Inc. currently loses $16.

Fundamentals & Financials

Revenue (TTM)
$945.5M
Net Income (TTM)
-$570.2M
EPS (TTM)
-$3.04
ROA (TTM)
-26.38%
Current Ratio
2.09
Dividend Yield
0.021%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-23.8%Q2 2026-$0.84
-35.5%Q3 2026-$0.78
+22.5%Q4 2026-$0.42

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +22.5%

BridgeBio Pharma’s third fiscal quarter of 2026 results topped consensus on EPS, with preliminary figures reported October 29, 2026 showing EPS of -$0.42 topping the -$0.54 estimate by $0.12. Revenue rose ~110% year over year to about $253.3 million (up from roughly $120.7 million a year ago), while net income narrowed to a loss of about $83.0 million, improving ~55% from a loss of roughly $182.7 million a year earlier alongside EPS improving ~56% from -$0.95. Profitability was reflected in gross profit of about $245.2 million and a gross margin near 97%. Cash generation remained negative, with negative operating cash flow of about $44.2 million, while the company reported repurchasing about $38.2 million of stock and paying roughly $2.7 million in dividends during the period. Consensus for the next period calls for EPS of -$0.53.

View full earnings history

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a NASDAQ-listed biotechnology company that develops medicines for genetic diseases, cancer-related conditions, and gene therapy applications. In FY2025, it generated $502.1 million of revenue. Founded in 2015 and based in Palo Alto, California, BridgeBio builds its business around a broad clinical pipeline and partnered research base.

Name
BridgeBio Pharma, Inc.
CEO
Neil Kumar
Industry
Healthcare
Year Founded
2015
Employees
1,001

Today's Snapshot

AI-generated

BBIO closed 1.6% above yesterday's close, outperforming a weaker sector. Volume was about a quarter more than its usual level.

Trading Volume

Above 10d avg 2.5M

3.5M

vs S&P 500 Today

Outperforming Market

+1.84%

Updated: November 18, 2026 at 21:08 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
BBIO at 78.01 displays a bullish technical profile with price above short, medium and the 200‑day averages (200‑day about $72.7) and a strong ADX reading near 38, indicating a robust trend. Momentum indicators are supportive, with MACD positive and RSI in bullish territory, while OBV confirms buying pressure. Volatility is moderate with ATR around 3.4% and the pivot at 76.22 sits below the market, providing a near support reference. Overall these elements align in favor of the buy signal. Technical takeaway: Strong Buy — trending strength with supportive momentum and volume.
All signals
  • EMA (5 indicators)$72.57 - $76.95
    Buy
  • RSI (14)62.39
    Neutral
  • Stochastic %K (14, 3, 3)67.39
    Neutral
  • MACD Level (12, 26)2.38
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.